Skip to main content

Table 2: Univariate analysis of prognostic factors for overall survival and time to progression

From: Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study

Variables

OS

TTP

HR (95% CI)

P value

HR (95% CI)

P value

Gender

    

Male

1

 

1

 

Female

1.213 (0.694, 2.119)

0.498

0.701 (0.415, 1.183)

0.183

Age (years)

1.003 (0.984, 1.023)

0.750

1.003 (0.986, 1.021)

0.715

Bilirubin (µmol/L)

1.003 (0.986, 1.020)

0.759

1.004 (0.990, 1.019)

0.548

Albumin (g/L)

1.021 (0.983, 1.060)

0.278

0.999 (0.967, 1.033)

0.972

PT (s)

0.943 (0.816, 1.089)

0.423

1.006 (0.891, 1.136)

0.921

AST (µmol/L)

1.004 (0.997, 1.010)

0.294

1.005 (0.999, 1.011)

0.116

Tumor size

1.179 (1.105, 1.257)

0.000

1.132 (1.066, 1.201)

0.000

Tumor number

1.326 (0.873, 2.015)

0.186

1.489 (1.032, 2.150)

0.033

Hepatitis

    

Hepatitis B

1

 

1

 

Other

0.861 (0.468, 1.584)

0.630

1.216 (0.704, 2.100)

0.483

α-Fetoprotein level

    

 ≥ 400 ng/mL

1

 

1

 

 < 400 ng/ml

1.843 (1.169, 2.906)

0.008

1.738 (1.135, 2.662)

0.011

Child–Pugh score

    

A

1

 

1

 

B

0.575 (0.337, 0.980)

0.042

0.614 (0.373, 1.010)

0.055

BCLC stage

    

A

1

   

B

0.348 (0.217, 0.559)

0.000

0.472 (0.319, 0.700)

0.000

TACE sessions

    

1

1

 

1

 

2 or more

0.968 (0.901, 1.040)

0.372

1.050 (0.991, 1.114)

0.101

Treatment method

    

Early-RFA

1

   

Late-RFA

0.573 (0.365, 0.898)

0.015

0.351 (0.230, 0.535)

0.000

  1. OS: Overall survival; TTP: Time to progression; HR: Hazard ratio; CI: Confidence interval; PT: Prothrombin time; AST: Aspartate aminotransferase; BCLC: Barcelona Clinic Liver Cancer; TACE: Transcatheter arterial chemoembolization; RFA: Radiofrequency ablation
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us